Aptose Biosciences Files 8-K

Ticker: APTOF · Form: 8-K · Filed: Mar 17, 2025 · CIK: 882361

Sentiment: neutral

Topics: 8-K, financial-reporting, regulatory-disclosure

TL;DR

Aptose Biosciences filed an 8-K on 3/17/25 with financial updates.

AI Summary

Aptose Biosciences Inc. filed an 8-K on March 17, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is incorporated in Canada and operates in the Biological Products sector.

Why It Matters

This filing provides important updates on Aptose Biosciences' financial status and regulatory disclosures, which are crucial for investors to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting financial statements and exhibits, with no immediate indication of significant new risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Aptose Biosciences Inc.?

The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits as of March 17, 2025.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on March 17, 2025.

What industry does Aptose Biosciences Inc. operate in?

Aptose Biosciences Inc. operates in the Biological Products sector, specifically under the SIC code 2836.

What were some of the former names of Aptose Biosciences Inc.?

Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc.

In which jurisdiction is Aptose Biosciences Inc. incorporated?

Aptose Biosciences Inc. is incorporated in Canada.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 17, 2025 regarding Aptose Biosciences Inc. (APTOF).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing